Results 31 to 40 of about 11,390 (145)

Fulvestrant May Falsely Increase 17β-Estradiol Levels in Immunoassays: A Case Report of a 57-Year-Old Postmenopausal Patient With Recurrent Estrogen Receptor-Positive Breast Cancer

Frontiers in Oncology, 2022
The prognosis for female patients with locoregionally recurrent breast cancer has improved with the concurrent local and systemic treatment under multiple disciplinary teams.
Jingxian Ding, Yali Cao, Yonghong Guo
doaj   +1 more source

Annual Banned‐Substance Review 18th Edition—Analytical Approaches in Human Sports Drug Testing 2024/2025

Drug Testing and Analysis, EarlyView.
New insights into drug metabolism, distribution, elimination, and detection assays for drugs and methods of sports doping published between 2024 and 2025 are critically reviewed and evaluated in context with the Prohibited List 2025 as established by the World Anti‐Doping Agency.
Mario Thevis, Tiia Kuuranne, Hans Geyer
wiley   +1 more source

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

International Journal of Cancer, EarlyView.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke‐Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel   +20 more
wiley   +1 more source

Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database

Scientific Reports
Fulvestrant, as the first selective estrogen receptor degrader, is widely used in the endocrine treatment of breast cancer. However, in the real world, there is a lack of relevant reports on adverse reaction data mining for fulvestrant.
Guisen Yin, Guiling Song, Shuyi Xue, Fen Liu   +3 more
doaj   +1 more source

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review

Therapeutic Advances in Medical Oncology, 2017
We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer.
Tomás Reinert, Carlos H. Barrios
doaj   +1 more source

Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer - A Chinese healthcare system perspective

Frontiers in Oncology, 2023
AimTo evaluate the cost-effectiveness of palbociclib plus fulvestrant in the second-line treatment of women with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer based on the latest published follow ...
Wentao Zhu, Miaomiao Zheng, Panpan Xia, Wanglong Hong, Guoqiang Ma, Aizong Shen, Aizong Shen   +6 more
doaj   +1 more source

Long‐term benefit from adjuvant tamoxifen therapy for ER+ HER2− breast cancer by PR positivity

International Journal of Cancer, EarlyView.
What's New? Tamoxifen is a cornerstone of endocrine therapy for estrogen receptor (ER)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative breast cancer. Its long‐term benefits, however, may vary by progesterone receptor (PR) status. Here, using data from the Stockholm tamoxifen trials, the authors evaluated whether PR expression predicts
Anna E. Nordenskjöld, Magdalena Ríos‐Romero, Huma Dar, Tommy Fornander, Gizeh Perez‐Tenorio, Helena Fohlin, Olle Stål, Julia Tutzauer, Linda S. Lindström   +8 more
wiley   +1 more source

Pharmacophore modeling for identification of anti-IGF-1R drugs and in-vitro validation of fulvestrant as a potential inhibitor. [PDF]

PLoS ONE, 2018
Insulin-like growth factor 1 receptor (IGF-1R) is an important therapeutic target for breast cancer treatment. The alteration in the IGF-1R associated signaling network due to various genetic and environmental factors leads the system towards metastasis.
Samra Khalid, Rumeza Hanif, Ishrat Jabeen, Qaisar Mansoor, Muhammad Ismail   +4 more
doaj   +1 more source

The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer

Current Oncology, 2022
Background: Palbociclib, a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, in combination with letrozole or fulvestrant has been demonstrated to prolong the progression-free survival (PFS) in patients with hormone receptor-positive (HR+), human ...
Fulbert Fu, Jessica Kano, Julia Ma, Mera Guindy   +3 more
doaj   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source